XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young-Hoon | - |
dc.contributor.author | Shim, Jaemin | - |
dc.contributor.author | Tsai, Chia-Ti | - |
dc.contributor.author | Wang, Chun-Chieh | - |
dc.contributor.author | Vilela, Gilbert | - |
dc.contributor.author | Muengtaweepongsa, Sombat | - |
dc.contributor.author | Kurniawan, Mohammad | - |
dc.contributor.author | Maskon, Oteh | - |
dc.contributor.author | Hsu, Li Fern | - |
dc.contributor.author | Thang Huy Nguyen | - |
dc.contributor.author | Thanachartwet, Thititat | - |
dc.contributor.author | Sim, Kenneth | - |
dc.contributor.author | Camm, A. John | - |
dc.date.accessioned | 2021-09-02T08:00:01Z | - |
dc.date.available | 2021-09-02T08:00:01Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-08 | - |
dc.identifier.issn | 1880-4276 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/73858 | - |
dc.description.abstract | BackgroundROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban was non-inferior to warfarin for stroke/systemic embolism (SE) prevention in patients with non-valvular atrial fibrillation (NVAF), with a favorable benefit-risk profile. XANAP investigated the safety and effectiveness of rivaroxaban in routine care in Asia-Pacific. MethodsXANAP was a prospective, real-world, observational study in patients with NVAF newly starting rivaroxaban. Patients were followed at 3-month intervals for 1 year, or for 30 days after permanent discontinuation. Primary outcomes were major bleeding events, adverse events (AEs), serious AEs and all-cause mortality; secondary outcomes included stroke/SE. Major outcomes were adjudicated centrally. ResultsXANAP enrolled 2273 patients from 10 countries: mean age was 70.5 years and 58.1% were male. 49.8% of patients received rivaroxaban 20 mg once daily (od), 43.8% 15 mg od and 5.9% 10 mg od. Mean treatment duration was 296 days, and 72.8% of patients had received prior anticoagulation therapy. Co-morbidities included heart failure (20.1%), hypertension (73.6%), diabetes mellitus (26.6%), prior stroke/non-central nervous system SE/transient ischemic attack (32.8%) and myocardial infarction (3.8%). Mean CHADS(2), CHA(2)DS(2)-VASc and HAS-BLED scores were 2.3, 3.7 and 2.1, respectively. The rates (events/100 patient-years [95% confidence interval]) of treatment-emergent major bleeding, stroke and all-cause mortality were 1.5 (1.0-2.1), 1.7 (1.2-2.5) and 2.0 (1.4-2.7), respectively. Persistence was 66.2% at the study end. ConclusionsThe real-world XANAP study demonstrated low rates of stroke and bleeding in rivaroxaban-treated patients with NVAF from Asia-Pacific. The results were consistent with the real-world XANTUS study and ROCKET AF. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | ROCKET AF TRIAL | - |
dc.subject | ORAL ANTICOAGULANTS | - |
dc.subject | VS. WARFARIN | - |
dc.subject | EPIDEMIOLOGY | - |
dc.subject | DABIGATRAN | - |
dc.subject | DISEASE | - |
dc.subject | SAFETY | - |
dc.title | XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Young-Hoon | - |
dc.contributor.affiliatedAuthor | Shim, Jaemin | - |
dc.identifier.doi | 10.1002/joa3.12073 | - |
dc.identifier.scopusid | 2-s2.0-85054738871 | - |
dc.identifier.wosid | 000443564200011 | - |
dc.identifier.bibliographicCitation | JOURNAL OF ARRHYTHMIA, v.34, no.4, pp.418 - 427 | - |
dc.relation.isPartOf | JOURNAL OF ARRHYTHMIA | - |
dc.citation.title | JOURNAL OF ARRHYTHMIA | - |
dc.citation.volume | 34 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 418 | - |
dc.citation.endPage | 427 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | ROCKET AF TRIAL | - |
dc.subject.keywordPlus | ORAL ANTICOAGULANTS | - |
dc.subject.keywordPlus | VS. WARFARIN | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | DABIGATRAN | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Asia-Pacific | - |
dc.subject.keywordAuthor | bleeding risk | - |
dc.subject.keywordAuthor | real world | - |
dc.subject.keywordAuthor | rivaroxaban | - |
dc.subject.keywordAuthor | stroke prevention | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.